Serine threonine tyrosine kinase 1 is a potential prognostic marker in colorectal cancer

Hu, Liang; Chen, Haiyang; Cai, Jian; Qi, Chen-Ye; Gong, Hui; Zhai, Yan-Xia; Fu, Hao; Yang, Guosheng; Gao, Chunfang

doi:10.1186/s12885-015-1285-y

Cited by 27 publications

(26 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specimens were all confirmed by pathological analysis as colorectal cancer. Immunohistochemistry was performed as described earlier, using monoclonal antibodies against CD3 (SP7), CD8 (4B11), CD45RO (OPD4), CD57 (NK1), tryptase (AA1), CD1A (Ab‐5), granulocytes (BM‐2), PDPN (D2‐40), cytokeratin (AE1AE3), FOXP3 (ab20034; AbCam, Cambridge, United Kingdom) CD68 (PGM‐1), CD20 (L26; DAKO, Carpinteria, CA), IL3RA (IL3RA; ATLAS Antibodies, Stockholm, Sweden), CXCR5 and IL‐17 (H‐132; Santa Cruz Biotechnology, Santa Cruz, CA). Isotype‐matched mouse monoclonal antibodies were used as negative controls.…”

Section: Methodsmentioning

confidence: 99%

“…Immunohistochemistry F I G U R E 1 Flowchart detailing the study design and samples at each stage of analysis. TGCA, The Cancer Genome Atlas; GEO, Gene Expression Omnibus; CIBERSORT, Cell type Identification By Estimating Relative Subsets Of known RNA Transcripts; DFS, disease-free survival was performed as described earlier, 32,33 using monoclonal antibodies against CD3 (SP7), CD8 (4B11), CD45RO (OPD4), CD57 (NK1), tryptase (AA1), CD1A (Ab-5), granulocytes (BM-2), PDPN (D2-40), cytokeratin (AE1AE3), FOXP3 (ab20034; AbCam, Cambridge, United Kingdom) CD68 (PGM-1), CD20 (L26; DAKO, Carpinteria, CA), IL3RA (IL3RA; ATLAS Antibodies, Stockholm, Sweden), CXCR5 and IL-17 (H-132; Santa Cruz Biotechnology, Santa Cruz, CA). Isotype-matched mouse monoclonal antibodies were used as negative controls.…”

Section: Immunohistochemical Detection Of Immune Cell Typesmentioning

confidence: 99%

See 1 more Smart Citation

Profiles of immune infiltration in colorectal cancer and their clinical significant: A gene expression‐based study

et al. 2018

View full text Add to dashboard Cite

Immune infiltration of colorectal cancer (CRC) is closely associated with clinical outcome. However, previous work has not accounted for the diversity of functionally distinct cell types that make up the immune response. In this study, based on a deconvolution algorithm (known as CIBERSORT) and clinical annotated expression profiles, we comprehensively analyzed the tumor‐infiltrating immune cells present in CRC for the first time. The fraction of 22 immune cells subpopulations was evaluated to determine the associations between each cell type and survival and response to chemotherapy. As a result, profiles of immune infiltration vary significantly between paired cancer and paracancerous tissue and the variation could characterize the individual differences. Of the cell subpopulations investigated, tumors lacking M1 macrophages or with an increased number of M2 macrophages, eosinophils, and neutrophils were associated with the poor prognosis. Unsupervised clustering analysis using immune cell proportions revealed five subgroups of tumors, largely defined by the balance between macrophages M1, M2, and NK resting cells, with distinct survival patterns, and associated with well‐established molecular subtype. Collectively, our data suggest that subtle differences in the cellular composition of the immune infiltrate in CRC appear to exist, and these differences are likely to be important determinants of both prognosis and response to treatment.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Immunohistochemical Detection Of Immune Cell Typesmentioning

confidence: 99%

Profiles of immune infiltration in colorectal cancer and their clinical significant: A gene expression‐based study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Expression of A20 in the tissue chip was evaluated in a blinded manner without prior knowledge of the clinical data using the German immunoreactive score (IRS) [ 21 ]. The median value of the IRS was chosen as the cut-off for high and low A20 expression levels based on a measure of heterogeneity according to the log-rank test with respect to the overall survival as described previously [ 22 , 23 ].…”

Section: Methodsmentioning

confidence: 99%

A20 suppresses hepatocellular carcinoma proliferation and metastasis through inhibition of Twist1 expression

Chen

Luo

et al. 2015

Mol Cancer

Self Cite

View full text Add to dashboard Cite

BackgroundAberrant expression of A20 has been reported in several human malignancies including hepatocellular carcinoma (HCC). However, its clinical relevance and potential role in HCC remain unknown.MethodsQuantitative PCR, Western blots and immunohistochemistry analyses were used to quantify A20 expression in HCC samples and cell lines. The correlation of A20 expression with clinicopathologic features was analyzed in a cohort containing 143 patients with primary HCC. Kaplan-Meier curves were used to evaluate the association between A20 expression and patient survival. Functional studies were performed to determine the effects of A20 on proliferation and metastasis of HCC cells in vitro and in vivo.ResultsExpression of A20 was increased in HCC tissues and cell lines. Increased expression of A20 was negatively correlated with the tumor size, TNM stage, tumor thrombus formation, capsular invasion and serum AFP levels. Patients with higher A20 expression had a prolonged disease-free survival and overall survival than those with lower A20 expression. Forced expression of A20 significantly inhibited the proliferative and invasive properties of HCC cells both in vitro and in vivo, whereas knockdown of A20 expression showed the opposite effects. Further studies revealed that expression of A20 was inversely correlated with Twist1 levels and NF-κB activity in HCC tissues and cell lines. A20-induced suppression of proliferation and migration of HCC cells were mainly mediated through inhibition of Twist1 expression that was regulated at least partly by A20-induced attenuation of NF-κB activity.ConclusionsOur results demonstrate that A20 plays a negative role in the development and progression of HCC probably through inhibiting Twist1 expression. A20 may serve as a novel prognostic biomarker and potential therapeutic target for HCC patients.Electronic supplementary materialThe online version of this article (doi:10.1186/s12943-015-0454-6) contains supplementary material, which is available to authorized users.

show abstract

“…Then, the sections were microwaved in 10 mM citrate buffer (pH 6.0) at 95°C for 20 min to perform antigen retrieval. After being blocked with goat serum for 30 min, the sections were incubated with the primary antibody (anti-Styk1 ab97451, 20 anti-AKT1 (phospho S473) ab81283, 21 anti-pan-AKT (phospho T308) ab38449, 22 anti-GSK3 beta (phospho Y216) ab75745, 23 anti-GSK3 beta (phospho S9) ab75814, 24 anti-E Cadherin ab40772 25,26 from Abcam, Cambridge, UK; and N-cadherin (D4R1H) 27 from Cell Signaling Technology, Danvers, MA, USA) at 4°C overnight. After being washed in PBS (phosphate-buffered saline), the sections were incubated with the appropriate horseradish peroxidase (HRP)-labeled goat anti-rabbit/mouse antibodies.…”

Section: Immunohistochemistrymentioning

confidence: 99%

<p>Aberrantly High Expression Of NOK/STYK1 Is Tightly Associated With The Activation Of The AKT/GSK3β/N-Cadherin Pathway In Non-Small Cell Lung Cancer</p>

Huang

Xiong

et al. 2019

OTT

View full text Add to dashboard Cite

High metastasis is a leading risk factor for the survival of non-small cell lung cancer (NSCLC) and epithelial-mesenchymal transition (EMT) is a vital step of metastasis. The expression of novel oncogene with kinase domain (NOK) has been observed in some human malignancies, including non-small cell lung cancer (NSCLC); however, the biological function of NOK in NSCLC remains unclear. In the study, we explored the function of NOK in NSCLC, with an aim to elucidate the relevant underlying mechanisms. Patients and methods: We investigate the expression of NOK, p-Akt, p-GSK-3β, E-cadherin and N-cadherin expression by immunohistochemical analysis using tissue microarrays of 72 paired NSCLC samples of cancerous and adjacent normal tissues. The associations between NOK expression and clinicopathological factors, overall survival, other proteins were assessed. Immunofluorescence analysis of NSCLC tissues was performed to study the location of NOK, Akt and GSK-3β. Up or down-regulated of NOK were conducted in two NSCLC cell lines to analyze its impact on AKT/GSK3β pathway. Results: Statistical analysis revealed NOK expression increased in NSCLC tissues compared with normal tissues (P<0.05). It also showed that low NOK expression were associated with a higher possibility of non-lymphatic metastasis, an early pN stage and clinical stage (P<0.05). Moreover, NOK expression was positively correlated with the expression of oncogene p-Akt (Thr308), p-GSK-3β (Ser9) and N-cadherin (P<0.05). Immunofluorescence analysis of NSCLC tissues revealed that NOK is co-located with Akt and GSK-3β. Further study in NSCLC cell lines revealed that NOK overexpression can activate the AKT/GSK3β pathway. Conversely, knockdown of NOK can suppress the AKT/GSK3β pathway. Conclusion: Our results suggest that NOK overexpression correlated significantly with lymphatic metastasis, advanced pN and clinical stage in NSCLC. And NOK may promote EMT by activating the AKT/GSK3β/N-cadherin pathway in NSCLC.

show abstract

Serine threonine tyrosine kinase 1 is a potential prognostic marker in colorectal cancer

Cited by 27 publications

References 27 publications

Profiles of immune infiltration in colorectal cancer and their clinical significant: A gene expression‐based study

Profiles of immune infiltration in colorectal cancer and their clinical significant: A gene expression‐based study

A20 suppresses hepatocellular carcinoma proliferation and metastasis through inhibition of Twist1 expression

<p>Aberrantly High Expression Of NOK/STYK1 Is Tightly Associated With The Activation Of The AKT/GSK3β/N-Cadherin Pathway In Non-Small Cell Lung Cancer</p>

Contact Info

Product

Resources

About